<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106179</url>
  </required_header>
  <id_info>
    <org_study_id>S_Hemangioma</org_study_id>
    <nct_id>NCT05106179</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma</brief_title>
  <official_title>The Efficacy and Safety of Beta-blockers Drugs in Adults With Spinal Hemangioma: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Vascular Pathology, Moscow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Vascular Pathology, Moscow</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal hemangioma is one of the most common benign vertebral tumours. Being mostly&#xD;
      asymptomatic, it is still associated with a pain syndrome especially if encroaches into the&#xD;
      neural canal.&#xD;
&#xD;
      This study is organised to evaluate the efficacy and safety of β-blockers drugs in adults&#xD;
      with spinal hemangioma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reducing tumor growth</measure>
    <time_frame>3 months</time_frame>
    <description>MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reducing tumor</measure>
    <time_frame>6 months</time_frame>
    <description>MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Life-quality</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Valid questionnaires based on the ones, approved by EuroQol Organization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Spinal Tumor</condition>
  <condition>Spinal Hemangioma</condition>
  <condition>Beta Blocker Toxicity</condition>
  <arm_group>
    <arm_group_label>Previously treated + Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previously treated + Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators suppose the outcome might be compromised if patient has been previously treated, that's why it is going to be compared to the main cohort. The results are going to be analysed separately</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol Pill</intervention_name>
    <description>Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.</description>
    <arm_group_label>Previously treated + Atenolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol Pill</intervention_name>
    <description>Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.</description>
    <arm_group_label>Previously treated + Propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  vertebral hemangioma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  symptomatic bradycardia&#xD;
&#xD;
          -  AV block&#xD;
&#xD;
          -  decompensated heart failure&#xD;
&#xD;
          -  asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterina Listovskaia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Vascular Anomalies Center (VAC) &quot;Hemangioma&quot;,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitry Romanov, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Vascular Anomalies Center (VAC) &quot;Hemangioma&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Vascular Anomalies Center (VAC) &quot;Hemangioma&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>109028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>β-blockers</keyword>
  <keyword>Vertebral Hemangioma</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
    <mesh_term>Spinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

